Amsterdam 2013 Programme Satellite Meetings Registration Exhibition Virtual Exhibition Hotels Visa Letter Invitation
Search Abstracts by author or title
(results will display both Free Papers & Poster)

Ozurdex treatment of chronic refractory irwing-gass syndrome

Poster Details

First Author: M.Ratkovi? CROATIA

Co Author(s):    R. Lazic   I. Boras   N. Gabric        

Abstract Details



Purpose:

To present our results of 4 patients with persistent refractory pseudophakic cystoid macular edema (PCME) treated with Ozurdex (dexamethasone intravitreal implants).

Setting:

University Eye Hospital Svjetlost, Zagreb, Croatia

Methods:

4 eyes 6 months after the cataract surgery with chronic PCME refarctory to NSAIDs , and corticosteroid periocular and intraocular injection therapy. 4 eyes were treated with single Ozurdex (dexamethasone intravitreal implant) injection and followed up 1 month, and 3 months after the injection was administered.

Results:

Patient 1. Baseline BCVA 0.30 ; macular thickness 403 ?m. 3 months after the injection BCVA 0.65 ; macular thickness 260 ?m. Patient 2. Baseline BCVA 0.25 ; macular thickness 380 ?m. 3 months after the injection BCVA 0.70 ; macular thickness 244 ?m. Patient 3. Baseline BCVA 0.45 ; macular thickness 735 ?m. 3 months after the injection BCVA 0.85 ; macular thickness 289 ?m. Patient 4. Baseline BCVA 0.40 ; macular thickness 562 ?m. 3 months after the injection BCVA 0.70 ; macular thickness 301 ?m. No complications and no significant intraocular pressure increase were observed. 2 patients had mild subconjunctival hyperemia resolved 7 days after Ozurdex injection. 2 patients could see some vitreous opacification 10 days after the injection. 1 patient required limited monotherapy with antiglaucoma eyedrops.

Conclusions:

In this small case series Ozurdex sustained-release corticosteroid implant was benefitial in treating patients with chronic refractory PCME. Further larger and randomized clinical trials will investigate efficasy and safety of this treatment.

Financial Disclosure:

NONE

Back to previous